Literature DB >> 25619537

Treatment options for optic pathway gliomas.

Reena P Thomas1, Iris C Gibbs, Linda Wei Xu, Lawrence Recht.   

Abstract

OPINION STATEMENT: Gliomas that affect the optic pathways are for the most part low-grade neoplasms that often, but not always, have good prognoses. Optimal treatment and management of optic pathway gliomas remains unclear and the decision hinges upon several factors including patient age, tumor location, and visual symptoms. We favor a treatment approach that is dependent on the location of tumor within anterior, chiasmal or posterior/hypothalamic visual pathways. In children who are minimally or not symptomatic, we recommend observation rather than early treatment intervention. Most of these patients will have neurofibromatosis type 1 (NF1) based on the natural history and their pilocytic astrocytoma histology. Serial magnetic resonance imaging studies and formal neuro-ophthalmology testing should enable close observation of these patients, with intervention being reserved for when tumor progression results in significant visual loss or proptosis. Chemotherapy is an accepted first line treatment, and a number of effective medications are available, although no agent has proven clearly superior. If progression is accompanied by the complete loss of vision, surgery can be utilized to help alleviate structural issues (ie, proptosis). Minimally symptomatic chiasmal or hypothalamic tumors that arise in the setting of NF1 can also be observed initially because of their favorable prognosis. Children with NF1 and chiasmal or posterior visual tumors who progress either on imaging or clinical grounds (ie, development of significant visual deficits) should be treated first with chemotherapy rather than radiation therapy to minimize the effects on the developing central nervous system. Individuals without NF1 presenting with a chiasmal or hypothalamic mass are candidates for biopsy to determine the underlying pathology of the lesion. Symptomatic patients with pilocytic astrocytoma should first receive chemotherapy. In contrast, other histologies including malignant optic pathway gliomas should be treated similar to other gliomas that occur in other locations with appropriate doses of radiation and chemotherapy.

Entities:  

Year:  2015        PMID: 25619537     DOI: 10.1007/s11940-014-0333-2

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  35 in total

1.  Visual function and optic pathway glioma: a critical response.

Authors:  David H Gutmann; Robert Avery; Rosalie E Ferner; Robert Listernick
Journal:  JAMA Ophthalmol       Date:  2013-01       Impact factor: 7.389

2.  Proton radiation therapy (PRT) for pediatric optic pathway gliomas: comparison with 3D planned conventional photons and a standard photon technique.

Authors:  M Fuss; E B Hug; R A Schaefer; M Nevinny-Stickel; D W Miller; J M Slater; J D Slater
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-12-01       Impact factor: 7.038

3.  Radiation therapy of optico-hypothalamic gliomas (OHG)--radiographic response, vision and late toxicity.

Authors:  G G Grabenbauer; U Schuchardt; M Buchfelder; C M Rödel; G Gusek; M Marx; H G Doerr; R Fahlbusch; W J Huk; D Wenzel; R Sauer
Journal:  Radiother Oncol       Date:  2000-03       Impact factor: 6.280

4.  Gamma Knife surgery in the management of orbital tumors.

Authors:  Desheng Xu; Dong Liu; Zhiyuan Zhang; Yipei Zhang; Yanhe Li; Xiaomin Liu; Qiang Jia; Ligao Zheng; Guoxiang Song
Journal:  J Neurosurg       Date:  2010-12       Impact factor: 5.115

5.  Visual outcomes in pediatric optic pathway glioma after conformal radiation therapy.

Authors:  Richard M Awdeh; Erin N Kiehna; Richard D Drewry; Natalie C Kerr; Barrett G Haik; Shengjie Wu; Xiaoping Xiong; Thomas E Merchant
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-05-18       Impact factor: 7.038

6.  Visual loss in children with neurofibromatosis type 1 and optic pathway gliomas: relation to tumor location by magnetic resonance imaging.

Authors:  L J Balcer; G T Liu; G Heller; L Bilaniuk; N J Volpe; S L Galetta; P T Molloy; P C Phillips; A J Janss; S Vaughn; M G Maguire
Journal:  Am J Ophthalmol       Date:  2001-04       Impact factor: 5.258

Review 7.  Neurofibromatosis 1.

Authors:  Timothy M Lynch; David H Gutmann
Journal:  Neurol Clin       Date:  2002-08       Impact factor: 3.806

Review 8.  Visual acuity in children with low grade gliomas of the visual pathway: implications for patient care and clinical research.

Authors:  Robert A Avery; Rosalie E Ferner; Robert Listernick; Michael J Fisher; David H Gutmann; Grant T Liu
Journal:  J Neurooncol       Date:  2012-07-28       Impact factor: 4.130

Review 9.  Optic pathway gliomas: a review.

Authors:  Mandy J Binning; James K Liu; John R W Kestle; Douglas L Brockmeyer; Marion L Walker
Journal:  Neurosurg Focus       Date:  2007       Impact factor: 4.047

Review 10.  Radiation therapy: orbital tumors.

Authors:  Gaurav Marwaha; Roger Macklis; Arun D Singh
Journal:  Dev Ophthalmol       Date:  2013-08-26
View more
  14 in total

1.  The Visual Acuity Outcome and Relevant Factors Affecting Visual Improvement in Pediatric Sporadic Chiasmatic-Hypothalamic Glioma Patients Who Received Surgery.

Authors:  Chihyi Liao; Heng Zhang; Zhiming Liu; Zhe Han; Chunde Li; Jian Gong; Wei Liu; Zhenyu Ma; Yongji Tian
Journal:  Front Neurol       Date:  2020-08-19       Impact factor: 4.003

2.  Treatment of neurofibromatosis type 1.

Authors:  Caterina Sabatini; Donatella Milani; Francesca Menni; Gianluca Tadini; Susanna Esposito
Journal:  Curr Treat Options Neurol       Date:  2015-06       Impact factor: 3.598

3.  Endoscopic transnasal resection of optic pathway pilocytic astrocytoma.

Authors:  Sarah Bin Abdulqader; Ziyad Al-Ajlan; Abdulrahman Albakr; Wisam Issawi; Mohammed Al-Bar; Pablo F Recinos; Saad Alsaleh; Abdulrazag Ajlan
Journal:  Childs Nerv Syst       Date:  2018-10-18       Impact factor: 1.475

4.  Long-term visual outcomes of optic pathway gliomas in pediatric patients without neurofibromatosis type 1.

Authors:  Michael J Wan; Nicole J Ullrich; Peter E Manley; Mark W Kieran; Liliana C Goumnerova; Gena Heidary
Journal:  J Neurooncol       Date:  2016-06-16       Impact factor: 4.130

Review 5.  Neurosurgical experience of managing optic pathway gliomas.

Authors:  Ciaran Scott Hill; Mehdi Khan; Kim Phipps; Katherine Green; Darren Hargrave; Kristian Aquilina
Journal:  Childs Nerv Syst       Date:  2021-02-03       Impact factor: 1.475

Review 6.  A systematic review of ongoing clinical trials in optic pathway gliomas.

Authors:  Ciaran Scott Hill; Sara Castro Devesa; William Ince; Anouk Borg; Kristian Aquilina
Journal:  Childs Nerv Syst       Date:  2020-06-18       Impact factor: 1.475

Review 7.  MRI-based diagnosis and treatment of pediatric brain tumors: is tissue sample always needed?

Authors:  Jehuda Soleman; Rina Dvir; Liat Ben-Sira; Michal Yalon; Frederick Boop; Shlomi Constantini; Jonathan Roth
Journal:  Childs Nerv Syst       Date:  2021-04-05       Impact factor: 1.475

8.  Treatment with endoscopic transnasal resection of hypothalamic pilocytic astrocytomas: a single-center experience.

Authors:  Zhuo-Ya Zhou; Xiao-Shu Wang; Yang Gong; Ode La Ali Musyafar; Jiao-Jiao Yu; Gang Huo; Jia-Min Mou; Gang Yang
Journal:  BMC Surg       Date:  2021-02-25       Impact factor: 2.102

9.  Comparison of two surgical methods for the treatment of optic pathway gliomas in the intraorbital segment: an analysis of long-term clinical follow-up, which evaluates the surgical outcomes.

Authors:  Peng Yang; Hao-Cheng Liu; E Qiu; Wei Wang; Jia-Liang Zhang; Li-Bin Jiang; Jun Kang
Journal:  Transl Pediatr       Date:  2021-06

Review 10.  Pediatric Optic Pathway/Hypothalamic Glioma.

Authors:  Yasuo Aihara; Kentaro Chiba; Seiichiro Eguchi; Kosaku Amano; Takakazu Kawamata
Journal:  Neurol Med Chir (Tokyo)       Date:  2017-11-09       Impact factor: 1.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.